Targeting antibiotic resistance mechanisms in Mycobacterium tuberculosis: recharging the old magic bullets

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/eri.12.85PMID 23106271PMCID PMC3970175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MDR, XDR, TDR tuberculosis: ominous progression

  2012cited by this paper
• The challenge of new drug discovery for tuberculosis

  2011cited by this paper
• Antibiotic resistance is ancient

  2011cited by this paper
• Current Prospects for the Fluoroquinolones as First-Line Tuberculosis Therapy

  2011cited by this paper
• [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].

  2009cited by this paper
• Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

  2009cited by this paper
• Synthetic EthR inhibitors boost antituberculous activity of ethionamide

  2009cited by this paper
• Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development.

  2009cited by this paper
• Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects.

  2009cited by this paper
• A synthetic mammalian gene circuit reveals antituberculosis compounds

  2008cited by this paper
• From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis

  2007cited by this paper
• Sampling the Antibiotic Resistome

  2006cited by this paper
• Incidence of Cross Resistance Between Rifampicin and Rifabutin in Mycobacterium tuberculosis Strains in Izmir, Turkey

  2005cited by this paper
• The magic bullets and tuberculosis drug targets.

  2005cited by this paper
• Rifapentine for the treatment of tuberculosis: is it all it can be?

  2004cited by this paper
• Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective

  2002cited by this paper
• From the analyst's couch. Trends in development cycles.

  2002cited by this paper
• Trends in development cycles

  2002cited by this paper
• Resisting resistance: new chemical strategies for battling superbugs.

  2000cited by this paper

• The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates

  2021cites this paper
• Antimicrobial activity of IDD-B40 against drug-resistant Mycobacterium tuberculosis

  2021cites this paper
• Re-sensitizing Ampicillin and Kanamycin-Resistant E. coli and S. aureus Using Synergistic Metal Micronutrients-Antibiotic Combinations

  2020cites this paper
• QSAR based therapeutic management of M. tuberculosis

  2017cites this paper
• QSAR based therapeutic management of M. tuberculosis

  2017cites this paper
• Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs

  2016cites this paper
• Antibiotic resistance mechanisms in M. tuberculosis: an update

  2016cites this paper
• Combinatorial active‐site variants confer sustained clavulanate resistance in BlaC β‐lactamase from Mycobacterium tuberculosis

  2015cites this paper
• Can mycobacterial genomics generate novel targets as speed-breakers against the race for drug resistance.

  2013cites this paper
• Molecular biology of drug resistance in Mycobacterium tuberculosis.

  2013cites this paper
• Comparison of the membrane proteome of virulent Mycobacterium tuberculosis and the attenuated Mycobacterium bovis BCG vaccine strain by label-free quantitative proteomics.

  2013cites this paper
• Tuberculosis: Challenges to Improve the Treatment.

  2013cites this paper